Estramustine, Docetaxel and Zoledronate Treatment in Hormone-Refractory Adenocarcinoma of the Prostate

NCT00151073 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

28

Enrollment

OTHER

Sponsor class

Conditions

Hormone-Refractory Prostate Cancer

Interventions

DRUG: Zoledronic acid
DRUG: Estramustine
DRUG: Docetaxel

Sponsor

University of Michigan Rogel Cancer Center

Collaborators

[object Object]
[object Object]